Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
Lumiracoxib is a selective inhibitor of COX-2 with IC50 values of 0.13 and 67 µM for COX-2 and COX-1, respectively, in isolated human whole blood.1 It reduces increases in the levels of prostaglandin E2 (PGE2; Item No. 14010) induced by IL-1β in human dermal fibroblasts (IC50 = 0.14 µM), as well as in LPS-stimulated RAW 264.7 cells when used at concentrations ranging from 1 to 100 µM.1,2 Lumiracoxib (3 and 10 mg/kg) also decreases LPS-induced increases in the levels of PGE2 in a rat model of air pouch inflammation.3 It reduces M. tuberculosis-induced increases in hind paw volume and the radiological and histopathological severity of arthritic lesions in a rat model of chronic arthritis when administered at a dose of 2 mg/kg.1
WARNING This product is not for human or veterinary use.
1. Preclinical pharmacology of lumiracoxib: a novel selective inhibitor of cyclooxygenase-
2. Different COX-
3. Pharmacodynamic behaviour of the selective cyclooxygenase-